{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:21:36Z","timestamp":1792095696530,"version":"4.4.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004322","name":"Agilent Technologies Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006034","name":"University of Southern California","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006034","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["968730"],"award-info":[{"award-number":["968730"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jconrel.2025.113930","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T02:48:37Z","timestamp":1749005317000},"page":"113930","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Clinically relevant dosing of miR-145 micelles curbs atherosclerosis in vivo"],"prefix":"10.1016","volume":"384","author":[{"given":"Isabella","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisa","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auveen","family":"Choroomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avery","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyla","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shino","family":"Magaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Vinters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Ji","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jconrel.2025.113930_bb0005","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis \u2014 An inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113930_bb0010","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/01.CIR.92.5.1355","article-title":"A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis","volume":"92","author":"Stary","year":"1995","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jconrel.2025.113930_bb0015","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.arcmed.2015.06.006","article-title":"Global overview of the epidemiology of atherosclerotic cardiovascular disease","volume":"46","author":"Barquera","year":"2015","journal-title":"Arch. Med. Res."},{"issue":"11","key":"10.1016\/j.jconrel.2025.113930_bb0020","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.clinthera.2023.09.020","article-title":"Global trends in atherosclerotic cardiovascular disease","volume":"45","author":"Nedkoff","year":"2023","journal-title":"Clin. Ther."},{"issue":"8","key":"10.1016\/j.jconrel.2025.113930_bb0025","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1161\/CIR.0000000000001209","article-title":"2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association","volume":"149","author":"Martin","year":"2024","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.jconrel.2025.113930_bb0030","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart disease and stroke statistics\u20142019 update: a report from the American Heart Association","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jconrel.2025.113930_bb0035","first-page":"24","article-title":"Emerging therapies for the treatment of atherosclerotic cardiovascular disease: from bench to bedside","author":"Kumric","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113930_bb0040","doi-asserted-by":"crossref","first-page":"207","DOI":"10.5551\/jat.RV17030","article-title":"Diagnosis and Management of Statin Intolerance","volume":"26","author":"Alonso","year":"2019","journal-title":"J. Atheroscler. Thromb."},{"issue":"11","key":"10.1016\/j.jconrel.2025.113930_bb0045","first-page":"e596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"issue":"9753","key":"10.1016\/j.jconrel.2025.113930_bb0050","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113930_bb0055","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2008.10.013","article-title":"The pathology of atherosclerosis: plaque development and plaque responses to medical treatment","volume":"122","author":"Insull","year":"2009","journal-title":"Am. J. Med."},{"issue":"8","key":"10.1016\/j.jconrel.2025.113930_bb0060","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1161\/ATVBAHA.116.307993","article-title":"Atherosclerotic plaque rupture","volume":"36","author":"Chen","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jconrel.2025.113930_bb0065","article-title":"miR-145 micelles mitigate atherosclerosis by modulating vascular smooth muscle cell phenotype","volume":"273","author":"Chung","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.113930_bb0070","doi-asserted-by":"crossref","DOI":"10.1039\/D4NH00613E","article-title":"Endothelial-targeting miR-145 micelles restore barrier function and exhibit atheroprotective effects","author":"Ashraf","year":"2025","journal-title":"Nanoscale Horiz"},{"key":"10.1016\/j.jconrel.2025.113930_bb0075","doi-asserted-by":"crossref","unstructured":"Patel, N.; Avery, E.; Huang, Y.; Chung, E. J. Developing Therapeutically Enhanced Extracellular Vesicles for Atherosclerosis Therapy. Adv. Healthcare Mater., 2404398. DOI: doi: https:\/\/doi.org\/10.1002\/adhm.202404398.","DOI":"10.1002\/adhm.202404398"},{"issue":"12","key":"10.1016\/j.jconrel.2025.113930_bb0080","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41569-019-0227-9","article-title":"Vascular smooth muscle cells in atherosclerosis","volume":"16","author":"Basatemur","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"issue":"11_suppl_1","key":"10.1016\/j.jconrel.2025.113930_bb0085","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1161\/CIRCULATIONAHA.111.084186","article-title":"MicroRNA-145 targeted therapy reduces atherosclerosis","volume":"126","author":"Lovren","year":"2012","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113930_bb0090","doi-asserted-by":"crossref","first-page":"42916","DOI":"10.1038\/srep42916","article-title":"Circulating miR-155, miR-145 and let-7c as diagnostic biomarkers of the coronary artery disease","volume":"7","author":"Faccini","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113930_bb0095","doi-asserted-by":"crossref","first-page":"R115","DOI":"10.1530\/VB-20-0012","article-title":"MicroRNA-145 targets in cancer and the cardiovascular system: evidence for common signaling pathways","volume":"2","author":"Sawant","year":"2020","journal-title":"Vascular Biology"},{"key":"10.1016\/j.jconrel.2025.113930_bb0100","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.bioactmat.2023.04.001","article-title":"Long-term, in vivo therapeutic effects of a single dose of miR-145 micelles for atherosclerosis","volume":"27","author":"Chin","year":"2023","journal-title":"Bioactive Materials"},{"issue":"2","key":"10.1016\/j.jconrel.2025.113930_bb0105","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/13506129.2016.1160882","article-title":"Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis","volume":"23","author":"Butler","year":"2016","journal-title":"Amyloid"},{"issue":"11","key":"10.1016\/j.jconrel.2025.113930_bb0110","article-title":"Preclinical development of a subcutaneous ALAS1 RNAi therapeutic for treatment of hepatic Porphyrias using circulating RNA quantification","volume":"4","author":"Chan","year":"2015","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jconrel.2025.113930_bb0115","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.omtn.2016.12.003","article-title":"Preclinical and clinical advances of GalNAc-decorated nucleic acid therapeutics","volume":"6","author":"Huang","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jconrel.2025.113930_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fdgth.2022.836579","article-title":"Therapeutic response of miR-145 micelles on patient-derived vascular smooth muscle cells","volume":"4","author":"Patel","year":"2022","journal-title":"Frontiers in Digital Health"},{"issue":"11","key":"10.1016\/j.jconrel.2025.113930_bb0125","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1161\/01.CIR.0000158435.98035.8D","article-title":"Plaque Rupture After Short Periods of Fat Feeding in the Apolipoprotein E\u2013Knockout Mouse","volume":"111","author":"Johnson","year":"2005","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.jconrel.2025.113930_bb0130","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat. Nanotechnol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113930_bb0135","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.jconrel.2025.113930_bb0140","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 trial of RNAi therapeutic Givosiran for acute intermittent Porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"7823","key":"10.1016\/j.jconrel.2025.113930_bb0145","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"issue":"10427","key":"10.1016\/j.jconrel.2025.113930_bb0150","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jconrel.2025.113930_bb0155","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1200\/JCO.2004.08.176","article-title":"Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced Cancer?","volume":"22","author":"Shanafelt","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113930_bb0160","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-019-0748-z","article-title":"Noncoding RNAs in cancer therapy resistance and targeted drug development","volume":"12","author":"Wang","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2025.113930_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/cells9010220","article-title":"miRNAs as Influencers of Cell\u2013Cell Communication in Tumor Microenvironment","volume":"9","author":"Conti","year":"2020","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.jconrel.2025.113930_bb0170","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/bjh.15547","article-title":"Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma","volume":"183","author":"Seto","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"11","key":"10.1016\/j.jconrel.2025.113930_bb0175","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1124\/dmd.123.001446","article-title":"Pharmacokinetics and absorption, distribution, metabolism and excretion of RGLS4326 in mouse and monkey, an anti\u2013miR-17 oligonucleotide for the treatment of polycystic kidney disease","volume":"51","author":"Kamel","year":"2023","journal-title":"Drug Metab. Dispos."},{"issue":"12","key":"10.1016\/j.jconrel.2025.113930_bb0180","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113930_bb0185","first-page":"358","article-title":"Long-term storage of lipid-like nanoparticles for mRNA delivery","volume":"5","author":"Zhao","year":"2020","journal-title":"Bioact. Mater."},{"issue":"5","key":"10.1016\/j.jconrel.2025.113930_bb0190","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/j.ymthe.2022.04.004","article-title":"Overcoming the challenge of long-term storage of mRNA-lipid nanoparticle vaccines","volume":"30","author":"Young","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2025.113930_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2021.100991","article-title":"Strategies to deliver RNA by nanoparticles for therapeutic potential","volume":"83","author":"Cox","year":"2022","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.jconrel.2025.113930_bb0200","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jconrel.2022.11.022","article-title":"Optimization of storage conditions for lipid nanoparticle-formulated self-replicating RNA vaccines","volume":"353","author":"Kim","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113930_bb0205","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.cis.2014.07.015","article-title":"Aggregation kinetics and colloidal stability of functionalized nanoparticles","volume":"222","author":"Gambinossi","year":"2015","journal-title":"Adv. Colloid Interf. Sci."},{"issue":"12","key":"10.1016\/j.jconrel.2025.113930_bb0210","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1007\/s11095-010-0233-4","article-title":"Polymeric micelles in anticancer therapy: targeting, imaging and triggered release","volume":"27","author":"Oerlemans","year":"2010","journal-title":"Pharm. Res."},{"issue":"8","key":"10.1016\/j.jconrel.2025.113930_bb0215","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1073\/pnas.1200718109","article-title":"Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane","volume":"109","author":"Zuckerman","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.jconrel.2025.113930_bb0220","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10865-007-9147-y","article-title":"The impact of medication regimen factors on adherence to chronic treatment: a review of literature","volume":"31","author":"Ingersoll","year":"2008","journal-title":"J. Behav. Med."},{"key":"10.1016\/j.jconrel.2025.113930_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104304","article-title":"A lung targeted miR-29 mimic as a therapy for pulmonary fibrosis","volume":"85","author":"Chioccioli","year":"2022","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113930_bb0230","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1161\/01.ATV.14.1.133","article-title":"ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree","volume":"14","author":"Nakashima","year":"1994","journal-title":"Arteriosclerosis and Thrombosis: A Journal of Vascular Biology"},{"issue":"3","key":"10.1016\/j.jconrel.2025.113930_bb0235","first-page":"2266","article-title":"Atorvastatin inhibits endoplasmic reticulum stress through AMPK signaling pathway in atherosclerosis in mice","volume":"19","author":"Xiong","year":"2020","journal-title":"Exp. Ther. Med."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113930_bb0240","first-page":"504","article-title":"J. Obesity and obesity-induced inflammatory disease contribute to atherosclerosis: a review of the pathophysiology and treatment of obesity","volume":"11","author":"Henning","year":"2021","journal-title":"Am J Cardiovasc Dis"},{"issue":"23","key":"10.1016\/j.jconrel.2025.113930_bb0245","doi-asserted-by":"crossref","first-page":"13531","DOI":"10.1073\/pnas.1735526100","article-title":"Transdifferentiation of mouse aortic smooth muscle cells to a macrophage-like state after cholesterol loading","volume":"100","author":"Rong","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.jconrel.2025.113930_bb0250","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/MCA.0000000000000252","article-title":"Association between serum galectin-3 levels and coronary atherosclerosis and plaque burden\/structure in patients with type 2 diabetes mellitus","volume":"26","author":"Ozturk","year":"2015","journal-title":"Coron. Artery Dis."},{"issue":"10","key":"10.1016\/j.jconrel.2025.113930_bb0255","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1172\/JCI13005","article-title":"VCAM-1 is critical in atherosclerosis","volume":"107","author":"Ley","year":"2001","journal-title":"J. Clin. Invest."},{"issue":"23\u201324","key":"10.1016\/j.jconrel.2025.113930_bb0260","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.cca.2010.08.038","article-title":"Mechanisms of LDL oxidation","volume":"411","author":"Yoshida","year":"2010","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jconrel.2025.113930_bb0265","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1749-6632.2001.tb03943.x","article-title":"Scavenger receptors, oxidized LDL, and atherosclerosis","volume":"947","author":"Boullier","year":"2001","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"11","key":"10.1016\/j.jconrel.2025.113930_bb0270","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41419-024-07166-8","article-title":"Inflammation in atherosclerosis: pathophysiology and mechanisms","volume":"15","author":"Ajoolabady","year":"2024","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113930_bb0275","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41392-024-01840-1","article-title":"Macrophages in cardiovascular diseases: molecular mechanisms and therapeutic targets","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113930_bb0280","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1161\/ATVBAHA.119.312802","article-title":"Macrophages in atherosclerosis regression","volume":"40","author":"Barrett","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113930_bb0285","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41419-019-1400-0","article-title":"Altered mitochondrial quality control in Atg7-deficient VSMCs promotes enhanced apoptosis and is linked to unstable atherosclerotic plaque phenotype","volume":"10","author":"Nahapetyan","year":"2019","journal-title":"Cell Death Dis."},{"issue":"23","key":"10.1016\/j.jconrel.2025.113930_bb0290","doi-asserted-by":"crossref","DOI":"10.3390\/cells11233843","article-title":"The role of oxidative stress in atherosclerosis","volume":"11","author":"Batty","year":"2022","journal-title":"Cells"},{"issue":"19","key":"10.1016\/j.jconrel.2025.113930_bb0295","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910688","article-title":"Inhibition of atherosclerosis and liver steatosis by agmatine in western diet-fed apoe-knockout mice is associated with decrease in hepatic de novo lipogenesis and reduction in plasma triglyceride\/high-density lipoprotein cholesterol ratio","volume":"22","author":"Wi\u015bniewska","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.jconrel.2025.113930_bb0300","first-page":"375","article-title":"Clinical chemistry reference intervals for C57BL\/6J, C57BL\/6N, and C3HeB\/FeJ mice (Mus musculus)","volume":"55","author":"Otto","year":"2016","journal-title":"J. Am. Assoc. Lab. Anim. Sci."},{"issue":"10","key":"10.1016\/j.jconrel.2025.113930_bb0305","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1016\/j.ymthe.2022.08.024","article-title":"Anti-atherosclerotic therapies: milestones, challenges, and emerging innovations","volume":"30","author":"Hetherington","year":"2022","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.jconrel.2025.113930_bb0310","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s00467-020-04892-x","article-title":"Correction to: clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020","volume":"36","author":"Kashtan","year":"2021","journal-title":"Pediatr. Nephrol."},{"issue":"10","key":"10.1016\/j.jconrel.2025.113930_bb0315","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(17)30621-6","article-title":"Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study","volume":"18","author":"van Zandwijk","year":"2017","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.jconrel.2025.113930_bb0320","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/eurheartj\/ehaa898","article-title":"Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human phase 1b randomized, double-blind, placebo-controlled study","volume":"42","author":"T\u00e4ubel","year":"2021","journal-title":"Eur. Heart J."},{"issue":"11","key":"10.1016\/j.jconrel.2025.113930_bb0325","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","article-title":"Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours","volume":"122","author":"Hong","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2025.113930_bb0330","first-page":"25 (3)","article-title":"Trials and tribulations of MicroRNA therapeutics","author":"Seyhan","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2025.113930_bb0335","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jconrel.2019.10.007","article-title":"MicroRNA delivery through nanoparticles","volume":"313","author":"Lee","year":"2019","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2025.113930_bb0340","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24010787","article-title":"Nanoparticles in Clinical Trials: Analysis of Clinical Trials, FDA Approvals and Use for COVID-19 Vaccines","volume":"24","author":"Namiot","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"20","key":"10.1016\/j.jconrel.2025.113930_bb0345","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.031121","article-title":"Phenotypic switching of vascular smooth muscle cells in atherosclerosis","volume":"12","author":"Chen","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.jconrel.2025.113930_bb0350","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.nano.2018.12.014","article-title":"Mitochondria-targeted antioxidant delivery for precise treatment of myocardial ischemia-reperfusion injury through a multistage continuous targeted strategy","volume":"16","author":"Cheng","year":"2019","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2025.113930_bb0355","doi-asserted-by":"crossref","unstructured":"Xia, Y.; Zhang, X.; An, P.; Luo, J.; Luo, Y. Mitochondrial homeostasis in VSMCs as a central hub in vascular remodeling. Int. J. Mol. Sci. 2023, 24 (4). DOI: https:\/\/doi.org\/10.3390\/ijms24043483 From NLM.","DOI":"10.3390\/ijms24043483"},{"issue":"6","key":"10.1016\/j.jconrel.2025.113930_bb0360","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/jbm.a.37668","article-title":"Nanoparticle-based therapeutic strategies for mitochondrial dysfunction in cardiovascular disease","volume":"112","author":"Suzuki","year":"2024","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.jconrel.2025.113930_bb0365","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.redox.2017.04.021","article-title":"Mitochondria in endothelial cells: sensors and integrators of environmental cues","volume":"12","author":"Caja","year":"2017","journal-title":"Redox Biol."},{"issue":"22","key":"10.1016\/j.jconrel.2025.113930_bb0370","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21228764","article-title":"Reactive Oxygen Species: Modulators of Phenotypic Switch of Vascular Smooth Muscle Cells","volume":"21","author":"Badran","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2025.113930_bb0375","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1038\/s41467-025-57444-y","article-title":"Adipose progenitor cell-derived extracellular vesicles suppress macrophage M1 program to alleviate midlife obesity","volume":"16","author":"Zhou","year":"2025","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.jconrel.2025.113930_bb0380","doi-asserted-by":"crossref","first-page":"7297","DOI":"10.1007\/s00210-024-03140-5","article-title":"Comparative pharmacokinetic evaluation of nanoparticle-based vs. conventional pharmaceuticals containing statins in attenuating dyslipidaemia","volume":"397","author":"Cordina","year":"2024","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"issue":"6","key":"10.1016\/j.jconrel.2025.113930_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2024.101614","article-title":"Development of a PCSK9-targeted nanoparticle vaccine to effectively decrease the hypercholesterolemia","volume":"5","author":"Fang","year":"2024","journal-title":"Cell Reports Medicine"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925005504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925005504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T04:58:45Z","timestamp":1779512325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925005504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":77,"alternative-id":["S0168365925005504"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113930","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinically relevant dosing of miR-145 micelles curbs atherosclerosis in vivo","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113930","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113930"}}